Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

5.62
Delayed Data
As of Jul 27
 -0.01 / -0.18%
Today’s Change
5.02
Today|||52-Week Range
11.18
-28.86%
Year-to-Date
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Jul 18 / Zacks.com - Paid Partner Content
Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
Jul 15 / Zacks.com - Paid Partner Content
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Jul 18 / Zacks.com - Paid Partner Content
Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Jul 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close5.63
Today’s open5.71
Day’s range5.52 - 5.79
Volume2,323,723
Average volume (3 months)1,767,089
Market cap$717.8M
Dividend yield--
Data as of 07/27/2016

Growth & Valuation

Earnings growth (last year)-66.25%
Earnings growth (this year)+35.59%
Earnings growth (next 5 years)+5.61%
Revenue growth (last year)-13.14%
P/E ratioNM
Price/Sales9.86
Price/Book--

Competitors

 Today’s
change
Today’s
% change
SGYPSynergy Pharmaceutic...+0.15+3.77%
EGRXEagle Pharmaceutical...+1.21+2.65%
SGNTSagent Pharmaceutica...+0.05+0.23%
AMPHAmphastar Pharmaceut...0.000.00%
Data as of 07/27/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)-$0.27
Annual revenue (last year)$89.3M
Annual profit (last year)-$148.0M
Net profit margin-165.76%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Robert J. Mulroy
Head-
Corporate Operations
William M. McClements
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs